$240B
Growth gap by 2030
EY estimates the industry's growth gap could reach US$240 billion by 2030.
Frontier biotechnology platform
Molecular R&D for global healthcare NextGen
VOSTOK ONE is building a repeatable biotechnology development platform. Two priority programmes provide the starting point, three opportunities form the next evaluation wave, and the wider reserve keeps the platform open to future growth. VOSTOK ONE will be established in Masdar Free Zone, Abu Dhabi, UAE.
Market pressure
Global pharma is facing the renewal crisis
Patent cliffs, rising R&D costs and increasing clinical complexity are forcing pharmaceutical companies to acquire validated preclinical and clinical-stage assets faster than ever.
Patent cliff
Pipeline replacement pressure
Revenue from established products is declining faster than internal pipelines can replace it.
$2.1T
Life sciences M&A firepower
Record capacity for acquisitions and licensing transactions entering 2026 (EY Firepower Report 2026).
Pressure points
- Merck — Keytruda >$25B/year · patent expiry 2028
- BMS — Revlimid · Eliquis · Opdivo · portfolio down 12–16% in 2026
- J&J — Stelara losing market share · $10–15B revenue gap
Preclinical licensing & M&A (2025–2026)
- AlzeCure / Eli Lilly — $10M upfront · $1.01B total · preclinical
- Orionis / Novartis — $40M upfront · $1.44B total · discovery
- Insilico / Eli Lilly — $115M upfront · $2.75B total · preclinical platform
- J&J / Intra-Cellular Therapies — $14.6B · CNS acquisition
Operating model
Capital-efficient molecular engineering
VOSTOK ONE is not designed as a CRO or pharmaceutical services provider. It plans to own or control selected programmes and work with Scientific Teams and qualified external providers under applicable GxP requirements.
01 / Design
Molecular engineering, target selection and proprietary IP development.
Company-led
02 / Validate
Preclinical development under applicable GxP requirements, including GLP for nonclinical safety studies where required.
Qualified providers
03 / License
Programmes are prepared for licensing and strategic partnerships with pharmaceutical counterparties.
Upfronts · milestones · royalties
Platform logic
Focused on two programmes · built to expand
Two priority neurology programmes receive current capital and management attention. Three opportunities form the next evaluation wave, while six reserve and future-reserve concepts preserve long-term expansion potential. The eleven-concept funnel gives VOSTOK ONE room to scale without diluting its immediate focus.
Proprietary IP strategy
- Targeted molecular architecture
- International patent strategy
- Stage-gated programme selection
Outsourced validation
- Preclinical development under applicable GxP requirements
- Phase I and Phase II clinical trials under GCP, where appropriate
- Phase III clinical trials partnership
Pharma-facing monetisation
- Licensing pathways
- Strategic partnerships
- Series A and licensing readiness
Therapeutic focus
2 priority programmes · 9 concepts for the next wave
Current capital is concentrated on two priority programmes that share a somatotropin / IGF-1 production and purification axis. Three opportunities are under structured evaluation and six concepts form the reserve and future reserve. This keeps execution narrow while preserving a repeatable path to pipeline expansion.
Current priority · 2 programmes
Neurology · neuroprotection
Programme 01 — Ischaemic Stroke
Recombinant IGF-1-LONG hybrid protein. Neuroprotection of the ischaemic penumbra and activation of post-ischaemic neurogenesis via the IGF-1 receptor pathway.
Market signal: Merck KGaA and aptaTargets entered an agreement in October 2024 for the clinical development and commercialisation of ApTOLL in acute ischaemic stroke.
Neurology · autoimmune
Programme 02 — Multiple Sclerosis
Recombinant somatotropin and / or recombinant IGF-1 for neuroprotection and symptomatic reduction across relapsing-remitting and progressive MS.
Scientific foundation: rhIGF-1 stimulates T-regulatory cell proliferation and suppresses immune response in EAE mouse MS model (EMBO Molecular Medicine, peer-reviewed).
3 opportunities under evaluation · 6 reserve or future-reserve concepts
Reserve and future reserve
Vaccines and longevity reserve
Concepts addressing S. pneumoniae, influenza A/B, tuberculosis, rotavirus, HPV and cellular senescence.
Commercial edge: Broad-spectrum, polyvalent protection designed to bypass strain-matching vulnerabilities.
Opportunity under evaluation
Non-opioid genetic analgesia
Plasmid DNA vectors including Beta-endorphin, HNP-1/2/3 and IGF-1-long fusion proteins.
Commercial edge: Transient, non-addictive genetic analgesia and sustained neuroprotective intervention.
Opportunity under evaluation
Targeted cartilage regeneration
Fusion proteins combining MATN1 ligands with targeted growth factors including EGF, TGF, FGF and IGF.
Commercial edge: Precision cellular repair mechanisms as an alternative to invasive orthopaedics.
Opportunity under evaluation
Humanised monoclonal antibodies
Proprietary mAbs targeting Syndecan-1/CD138 and Legumain.
Commercial edge: Hybrid architecture engineered to amplify cytotoxicity while extending in vivo half-life.
The Team
Built to execute at every stage
The team brings together scientific leadership, clinical and regulatory operations, investment experience, and the relationships needed to build partnerships across markets.
Science & Intellectual Property
- 30+ patent families across 19 jurisdictions
- 20+ years of drug discovery and laboratory leadership
- National Best Vaccine Awards (×2) · Geneva International Salon Gold Medal
- Bethesda US Pharmaceutical Research Institute Diploma
- Russian Government Medal "Labour for the Good" · PhD, Biotechnology
Clinical & Regulatory Operations
- 500+ clinical trials managed across international sponsors
- Global portfolio management at a top-tier international CRO
- Certified foreign trade expertise across three jurisdictions
- Islamic finance and UAE-facing transaction experience
- MBA, Foreign Trade & Investments
Investment & Business Development
- 2,300+ investment transactions evaluated globally, including M&A
- Government Venture Fund Investment Committee experience
- Technology institution founding across Russia and Kazakhstan
- International corporate and patent leadership · PhD, Physics and Mathematics
Partnerships, Communications & Ecosystem
- Co-founded 2 biotechnology companies · 10 biotech patents
- Innovation recognition across 8 countries: Russia, Japan, Hong Kong, Germany, Switzerland, Cyprus, Serbia, USA
- 30 years of PR, IR and GR for Russian and international clients
- 150,000+ scientific talents identified across Russia, EU and CIS
Strategic localisation
Planned establishment in Abu Dhabi's innovation ecosystem
VOSTOK ONE will be established in Masdar Free Zone, Abu Dhabi, UAE. Masdar is planned as the company's corporate and biotechnology base for programme management, local hiring, qualified-provider coordination and international partnerships.
Planned company base
VOSTOK ONE will be established in Masdar Free Zone, Abu Dhabi, UAE.
Institutional partnerships
Designed to pursue appropriate relationships with UAE healthcare, research and innovation institutions.
Regional ecosystem access
Proximity to regulators, hospitals, research hubs and investors can accelerate development, validation and market access.
MENA relevance
Purpose-built for the MENA healthcare landscape
Culturally aligned clinical development
Clinical development pathways can be adapted to regional standards, healthcare priorities and institutional expectations.
Specialised therapeutic applications
The platform can support high-value human and veterinary healthcare markets, including specialised applications relevant to the Gulf region.
Investment opportunity
Proposed Stage I financing
$2M
Proposed SAFE
Proposed SAFE
Proposed US$60M post-money cap · 20% discount
The proposed Stage I round would fund defined preclinical, IP, regulatory and CMC milestones for Programme 01 (Ischaemic Stroke) and Programme 02 (Multiple Sclerosis), both on the somatotropin / IGF-1 axis, under applicable GxP requirements.
The 12-month target is to produce partner-relevant evidence for both priority programmes, strengthen the repeatable operating model and open Series A and licensing discussions with pharmaceutical partners.
Institutional runway
Use of funds
The proposed allocation concentrates the first 12 months on the two priority programmes, qualified-provider work, UAE formation and the operating foundation required for licensing and strategic partnerships.
$2M
Proposed Stage I round allocated to clear programme, team and Abu Dhabi operating milestones.
65% Outsourced R&D & Preclinical Development $1.3M
22% Core Team & Programme Operations $440k
7% UAE Formation, Infrastructure & Compliance $140k
6% Scientific Communications & Partner Engagement $120k
Investor FAQ
Key questions about VOSTOK ONE:
A concise reference section for investors, partners and AI search systems summarising the VOSTOK ONE platform, operating model, therapeutic focus and planned UAE establishment.
What is VOSTOK ONE?
VOSTOK ONE is a biotechnology development company that works with Scientific Teams to identify selected drug programmes and advance them through research, IP protection, preclinical development and, where appropriate, Phase I and Phase II clinical trials. VOSTOK ONE plans to own or control selected programmes and create value through licensing and strategic partnerships. VOSTOK ONE will be established in Masdar Free Zone, Abu Dhabi, UAE.
Where is VOSTOK ONE unique?
VOSTOK ONE combines programme governance, molecular engineering and IP strategy with access to Scientific Teams across the CIS region, focusing primarily on Russia, Kazakhstan, Belarus, Armenia and Uzbekistan. Qualified external providers conduct specialised work under applicable GxP requirements. VOSTOK ONE plans to own or control selected programmes and is not designed to provide contract R&D services.
What is the VOSTOK ONE business model?
VOSTOK ONE identifies and develops promising drug candidates with Scientific Teams. It creates value through licensing and strategic partnerships, with potential revenue from upfront payments, development and commercial milestones, and royalties.
Is VOSTOK ONE a drug discovery platform?
Yes. VOSTOK ONE is designed as a drug development and molecular engineering platform rather than a single-product biotechnology company. Its strategy is to select, structure and develop programmes across several medical areas while concentrating capital on defined priorities.
What therapeutic areas does VOSTOK ONE focus on?
VOSTOK ONE currently prioritises two neurology programmes: Ischaemic Stroke (IGF-1-LONG hybrid protein) and Multiple Sclerosis (somatotropin / IGF-1 axis). Three additional opportunities are under structured evaluation. Six vaccine, longevity and infectious-disease concepts form the reserve and future reserve. Together, they create an eleven-concept development pool with clear priorities for capital and management attention.
Does VOSTOK ONE conduct clinical development internally?
VOSTOK ONE plans to retain programme governance, molecular engineering and IP strategy. Qualified providers will conduct preclinical work and, where appropriate, Phase I and Phase II clinical trials under applicable GxP requirements, with GLP, GCP and GMP used only in the relevant context.
How does pharmaceutical licensing fit into the platform?
Pharmaceutical licensing is a core commercial pathway. VOSTOK ONE prepares selected programmes for partner evaluation by building scientific evidence, IP structure, preclinical documentation and a clear commercial case for pharma partners, strategic investors and licensing discussions.
Why is the UAE important for VOSTOK ONE?
Abu Dhabi can provide the international base for programme governance, financing, regulatory engagement, local team building and pharmaceutical partnerships. VOSTOK ONE will be established in Masdar Free Zone, Abu Dhabi, UAE.